A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine (CHALLENGE-MIG)

I5Q-MC-CGBD -

The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine.

Trial Summary

Age Range
18 - 75 years
Conditions the trial is for
Headache Disorders
What the trial is testing?
galcanezumab (LY2951742)
Could I receive a Placebo?
Yes
Enrollment Goal
580
Trial Dates
Dec 6, 2021 - May 23, 2023
How long will I be in the trial?
Your participation could last about 6 months and may include up to 6 visits to the study center.
Trial Phase
IV

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have migraines with or without aura

Participants Must Not:

  • Participants must not be allergic to certain types of drugs

  • Participants must not have had a heart attack or stroke in the last 6 months

  • Participants must not be pregnant or nursing

  • Participants must not have serious mood or anxiety disorders

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources